AntiCancer Inc. has received a $50,000 small businessinnovation research (SBIR) grant to test the cancer drug taxolin a mouse model of human cancer.
The company will transplant human prostate and ovariantumors into the corresponding organs in immunodeficient mice,which do not reject foreign tissue. These animals, termedMetaMouse, allow tumors to grow and spread as they did in thepatient.
The privately held San Diego company will collaborate closelywith the NCI during the study.
(c) 1997 American Health Consultants. All rights reserved.